Physician profile
Sonya M Knight
NPI 1558495283
$18,611.00
in general payments reported to CMS, 2019-2025
30 companies · $1,339 in 2025
The $1,339 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,744 · 2020: $4,825 · 2021: $2,025 · 2022: $578 · 2023: $417 · 2024: $682 · 2025: $1,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392 · Travel and Lodging: $685 · Education: $210 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.46 |
| Travel and Lodging | $684.97 |
| Education | $210.45 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14,680.18 | 2019-2025 | Rexulti |
| Abbvie INC. | $987.63 | 2021-2025 | |
| Brainsway USA INC | $752.80 | 2019-2025 | Deep Tms |
| Teva Pharmaceuticals USA, INC. | $406.79 | 2019-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $278.61 | 2020-2025 | Ingrezza, Ongentys |
| Allergan, INC. | $164.77 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $150.00 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.88 | 2020-2024 | Caplyta |
| Lundbeck LLC | $146.75 | 2019-2024 | Rexulti |
| Bausch Health US, LLC | $129.00 | 2019-2025 | Aplenzin |
| Pfizer INC. | $114.00 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $81.15 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.88 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $54.79 | 2019-2022 | |
| Amgen INC. | $48.37 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $47.52 | 2023 | Wakix |
| Vanda Pharmaceuticals INC. | $41.80 | 2024-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $41.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $37.99 | 2025 | Spravato |
| Collegium Pharmaceutical, INC. | $36.43 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $32.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.26 | 2025 | Cobenfy |
| Ucb, INC. | $22.89 | 2022 | |
| Neurelis, INC. | $20.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.20 | 2023 | Quviviq |
| Almatica Pharma LLC | $16.23 | 2022 | |
| Sk Life Science, INC. | $16.07 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.94 | 2021 | |
| Axsome Therapeutics, INC. | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.